DOP2021000027A - Compuestos de 2,6-diaminopiridina - Google Patents
Compuestos de 2,6-diaminopiridinaInfo
- Publication number
- DOP2021000027A DOP2021000027A DO2021000027A DO2021000027A DOP2021000027A DO P2021000027 A DOP2021000027 A DO P2021000027A DO 2021000027 A DO2021000027 A DO 2021000027A DO 2021000027 A DO2021000027 A DO 2021000027A DO P2021000027 A DOP2021000027 A DO P2021000027A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- formula
- diaminopyridine compounds
- diaminopyridine
- compound
- Prior art date
Links
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical class NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable de este, y el uso de los compuestos de Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726520P | 2018-09-04 | 2018-09-04 | |
| PCT/US2019/048788 WO2020051058A1 (en) | 2018-09-04 | 2019-08-29 | 2,6-diamino pyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000027A true DOP2021000027A (es) | 2021-03-15 |
Family
ID=67982138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000027A DOP2021000027A (es) | 2018-09-04 | 2021-02-16 | Compuestos de 2,6-diaminopiridina |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10781212B2 (es) |
| EP (1) | EP3846809B1 (es) |
| JP (1) | JP6813720B1 (es) |
| KR (1) | KR102365535B1 (es) |
| CN (1) | CN112601525B (es) |
| AR (1) | AR117640A1 (es) |
| AU (1) | AU2019334877B2 (es) |
| BR (1) | BR112021001881A2 (es) |
| CA (1) | CA3111725C (es) |
| CL (1) | CL2021000528A1 (es) |
| CO (1) | CO2021002768A2 (es) |
| CR (1) | CR20210085A (es) |
| DO (1) | DOP2021000027A (es) |
| EA (1) | EA202190302A1 (es) |
| EC (1) | ECSP21015267A (es) |
| ES (1) | ES2971802T3 (es) |
| IL (1) | IL280598B2 (es) |
| JO (1) | JOP20210039A1 (es) |
| MA (1) | MA53547A (es) |
| MX (1) | MX2021002472A (es) |
| PE (1) | PE20211595A1 (es) |
| PH (1) | PH12021550449A1 (es) |
| SG (1) | SG11202101687TA (es) |
| TW (1) | TWI714231B (es) |
| UA (1) | UA124917C2 (es) |
| WO (1) | WO2020051058A1 (es) |
| ZA (1) | ZA202100700B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI750685B (zh) * | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| JP7403661B2 (ja) * | 2019-12-24 | 2023-12-22 | 杭州中美華東製薬有限公司 | Ｋｈｋ阻害効果を有する化合物 |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| EP4313967A1 (en) | 2021-03-29 | 2024-02-07 | Gilead Sciences, Inc. | Khk inhibitors |
| WO2023151473A1 (zh) * | 2022-02-09 | 2023-08-17 | 上海研健新药研发有限公司 | 一种khk抑制剂，其制备方法和应用 |
| WO2024121183A1 (en) * | 2022-12-08 | 2024-06-13 | Boehringer Ingelheim International Gmbh | New cyanopyridine khk inhibitor compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2094709T3 (pl) * | 2006-09-20 | 2011-02-28 | Lilly Co Eli | Tiazolopirazolopirymidyny jako antagoniści receptora crf1 |
| TW201623286A (zh) * | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
| RS59286B1 (sr) * | 2014-05-15 | 2019-10-31 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze |
| US9809579B2 (en) | 2015-12-29 | 2017-11-07 | Pfizer Inc. | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
-
2019
- 2019-08-23 TW TW108130153A patent/TWI714231B/zh active
- 2019-08-27 AR ARP190102434A patent/AR117640A1/es unknown
- 2019-08-29 MX MX2021002472A patent/MX2021002472A/es unknown
- 2019-08-29 IL IL280598A patent/IL280598B2/en unknown
- 2019-08-29 KR KR1020217006473A patent/KR102365535B1/ko active IP Right Grant
- 2019-08-29 WO PCT/US2019/048788 patent/WO2020051058A1/en active Application Filing
- 2019-08-29 PE PE2021000355A patent/PE20211595A1/es unknown
- 2019-08-29 JP JP2020537626A patent/JP6813720B1/ja active Active
- 2019-08-29 US US16/555,075 patent/US10781212B2/en active Active
- 2019-08-29 AU AU2019334877A patent/AU2019334877B2/en active Active
- 2019-08-29 SG SG11202101687TA patent/SG11202101687TA/en unknown
- 2019-08-29 MA MA053547A patent/MA53547A/fr unknown
- 2019-08-29 EP EP19769621.4A patent/EP3846809B1/en active Active
- 2019-08-29 JO JOP/2021/0039A patent/JOP20210039A1/ar unknown
- 2019-08-29 BR BR112021001881-6A patent/BR112021001881A2/pt unknown
- 2019-08-29 CR CR20210085A patent/CR20210085A/es unknown
- 2019-08-29 CN CN201980057907.2A patent/CN112601525B/zh active Active
- 2019-08-29 EA EA202190302A patent/EA202190302A1/ru unknown
- 2019-08-29 UA UAA202100674A patent/UA124917C2/uk unknown
- 2019-08-29 ES ES19769621T patent/ES2971802T3/es active Active
- 2019-08-29 CA CA3111725A patent/CA3111725C/en active Active
-
2021
- 2021-02-01 ZA ZA2021/00700A patent/ZA202100700B/en unknown
- 2021-02-16 DO DO2021000027A patent/DOP2021000027A/es unknown
- 2021-03-01 CO CONC2021/0002768A patent/CO2021002768A2/es unknown
- 2021-03-02 PH PH12021550449A patent/PH12021550449A1/en unknown
- 2021-03-03 CL CL2021000528A patent/CL2021000528A1/es unknown
- 2021-03-03 EC ECSENADI202115267A patent/ECSP21015267A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000027A (es) | Compuestos de 2,6-diaminopiridina | |
| CL2021003342A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
| DOP2021000273A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| CL2022003395A1 (es) | Antagonistas del receptor de lpa y usos de los mismos | |
| PE20191243A1 (es) | Nuevos derivados de fenilo | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| WO2014126944A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| MX2017000635A (es) | Inhibidores del canal de potasio medular externo renal. | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| AR113995A1 (es) | Moduladores de molécula pequeña del domino de btb de keap1 | |
| AR099767A1 (es) | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
| PE20190452A1 (es) | Derivado de triazolopirazinona util como un inhibidor de pde1 humana | |
| AR102248A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| AR109895A1 (es) | Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores | |
| AR119173A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| EA202192957A1 (ru) | Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| CL2018002677A1 (es) | Composición farmacéutica que comprende a) metformina, b) rosiglitazona o pioglitazona, c) sitagliptina, linagliptina o vildagliptina, y excipientes; y su uso para el tratamiento del desarrollo de ehna, sindrome de insulino-resistencia y la diabetes mellitus tipo 2, sop. | |
| AR108020A1 (es) | Moduladores de tgr5 y métodos de uso de los mismos | |
| CR9009A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias |